annual meeting program - American Society of Clinical Oncology

SATURDAY
Saturday, June 5, 2010
Brd. 18C United States (US) practices for chronic myelogenous leukemia (CML)
management compared to other countries: A worldwide observational
registry. (Abstract #6585)
R. C. Hermann, C. B. Miller, R. Catchatourian, D. Snyder, D. Williams, M. Juma,
J. E. Cortes
Brd. 18D Effect of the presence of P-glycoprotein (MDR1) on the ability of AML
patients to achieve complete remission: Results of a meta-analysis of the
literature. (Abstract #6586)
J. Marie, A. S. Lundberg, A. Ajami
Brd. 18E Safety and efficacy of HiDAC induction in de novo AML patients age 60 and
older. (Abstract #6587)
M. L. Arellano, L. Pan, L. Lima, M. Tighiouart, L. T. Heffner, A. A. Langston,
M. McLemore, J. Neely, E. F. Winton, H. J. Khoury
Brd. 18F Early intensification of imatinib treatment based on precise definition of
accelerated phase in patients with chronic myeloid leukemia: Populationbased
analysis. (Abstract #6588)
K. Foryciarz, T. Sacha, Z. Salamanczuk, M. Jakobczyk, S. Czekalska, M. Zawada,
M. Szostek, I. Florek, A. B. Skotnicki
Brd. 18G High-dose of daunorubicin as induction treatment for adults with newly
diagnosed Philadelphia-negative acute lymphoblastic leukemia. (Abstract
#6589)
S. Lee, Y. Joo, K. Lee, K. Kim, J. Ahn, S. Sohn, H. Kim, Y. Choi, J. Park, G. Lee,
Korean Society of Hematology, Adult ALL Working Party
Brd. 18H Prevalence of familial malignancy in a prospectively screened cohort of
patients with leukemia. (Abstract #6590)
A. Prasad, D. Liu, M. Rasul, N. Ahmed, K. Seiter
Brd. 19A Detection of combinations of cytogenetic abnormalities in chronic
lymphocytic leukemia (CLL) by fluorescent in situ hybridization (FISH)
probes. (Abstract #6591)
M. T. Schweizer, Y. Zhang, R. Kunnavakkam, T. Karrison, M. M. Le Beau,
R. A. Larson
Brd. 19B Molecular characterization of normal karyotype acute myeloid leukemia in
Korean patients. (Abstract #6592)
Y. Choi, J. Lee, D. Kim, J. Ahn, S. Lim, S. Kim, E. Hur, M. Seol, K. Lee
Brd. 19C Reactivation of latent viral hepatitis infection in patients of chronic myeloid
leukemia treated with imatinib mesylate: Experience from a tertiary cancer
center in India. (Abstract #6593)
V. Ostwal, N. Ghadyalpatil, K. Prabhash, H. Menon, R. Nair, M. Sengar,
V. Noronha, S. Biswas, B. Bhosale, S. Banavali
Brd. 19D Tuberculosis infection in chronic myeloid leukemia (CML) patients treated
with imatinib. (Abstract #6594)
N. Ghadyalpatil, K. Prabhash, H. Menon, R. Nair, S. Banavali, V. Noronha,
V. Wabale, R. Singh, G. Goyal, V. Ostwal
Brd. 19E Flow cytometric bead assay of BCR-ABL fusion proteins in leukemia
patients: An Indian experience. (Abstract #6595)
R. Pandey
Brd. 19F Meta-analysis of cord blood transplantations for indication of leukemia from
private umbilical cord blood banks from 1993–2009. (Abstract #6596)
N. Gottschalk, E. F. Lampeter, V. R. Jacobs
Brd. 19G Pulmonary hypertension (PH) in patients (pts) with CML treated with tyrosine
kinase inhibitors (TKIs). (Abstract #6597)
S. Gaballa, A. Al-Kali, H. Kantarjian, E. Jabbour, A. Quintas-Cardama, M. Ayoubi,
G. Borthakur, S. M. O’Brien, J. E. Cortes
Brd. 19H Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in
low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality.
(Abstract #6598)
P. Fenaux, A. Giagounidis, D. L. Selleslag, O. Beyne-Rauzy, M. Mittelman,
P. Muus, R. D. Knight, T. Fu, E. Hellstrom-Lindberg, The MDS-004 Len del(5q)
Study Group
96